- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00309127
Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy
A Multicentre, Randomised Study to Examine the Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Diabetic patients consume over 10% of health care costs in most developed countries. Over 80% of these resources are used to treat diabetic complications and late stage diseases. Over 30% of patients admitted to the medical wards in Hong Kong's public hospitals have diabetes, mainly due to cardiovascular and renal complications. Diabetes is now the leading cause of end stage renal disease (ESRD), accounting for 30-50% of patients on renal replacement therapy (RRT). In Hong Kong, the number of patients receiving RRT have increased by 50% in the last 5 years but the number of patients with ESRD due to diabetes have doubled. Between 10% and 15% of patients attending medical clinics in local public hospitals either receive insulin or anti-diabetic drugs. In both community and hospital settings, between 30% and 50% of diabetic patients have albuminuria, which is by far the most powerful predictor for early mortality, cardiovascular morbidity and renal disease. Local published data show that 3-10% of diabetic patients died or developed clinical endpoints yearly.
There are now overwhelming evidence supporting the beneficial effects of optimal control of cardiovascular risk factors on clinical outcomes in diabetic patients. However, there are few studies to examine the most effective way to translate these scientific evidence collected in closely monitored clinical trial situations into daily clinical practice. Results from this multi-centre, randomized study will provide important information to health care policy makers regarding the cost effectiveness of disease management using a multidisciplinary team to deliver a structured care model in light of the growing diabetes epidemic and the constraints of finite resources and the need for equity.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Hong Kong, Kina
- The Chinese University of Hong Kong
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Type 2 diabetic patients with ages between 35 and 75 years (inclusive) and defined according to the 1998 WHO criteria and no history of unprovoked ketosis and not requiring continuous insulin treatment within 1 year of diagnosis
- Plasma creatinine 150-350 mmol/l (inclusive) who had no microscopic haematuria and no ultrasonographic evidence of obstructive uropathy which is amenable to surgical intervention
Exclusion Criteria:
- patients with malignancy or other life-threatening diseases
- ultrasonographic evidence of obstructive uropathy which is amenable to surgical intervention
- non-diabetes related renal disease such as glomerulonephritis proven on renal biopsy reversible kidney disease, to be ruled out by ultrasonographic examination
- patients with clinically unstable psychiatric illnesses
- Patients who have 2 consecutive values of plasma creatinine concentration which differ by more than 20% within 3 months prior to recruitment.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Death and/or ESRD defined as need for dialysis or plasma creatinine 500mmol/l
Tidsram: May 2003 - Dec 2007
|
May 2003 - Dec 2007
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Composite cardiovascular endpoints (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia requiring hospital admissions, lower extremity amputation)
Tidsram: May 2003 - Dec 2007
|
May 2003 - Dec 2007
|
Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department
Tidsram: May 2003 - Dec 2007
|
May 2003 - Dec 2007
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Juliana CN Chan, MB ChB, MD, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CRE-2004.226-T
- HCPF No. 121012
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Typ 2-diabetes mellitus
-
Mathias Ried-LarsenAvslutadDiabetes mellitus, typ 2 | Typ 2-diabetes mellitus | Diabetes typ 2 | Typ 2 diabetes mellitusDanmark
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Caroline M KistorpRigshospitalet, Denmark; Herlev and Gentofte Hospital; Danish Heart FoundationAvslutadTyp 2 diabetes mellitusDanmark
-
TheracosAvslutadTyp 2 diabetes mellitusFörenta staterna
-
Biocon LimitedAvslutadJämförelse av insulin tregopil (IN-105) med insulin aspart hos patienter med typ 2-diabetes mellitusTyp 2 diabetes mellitusIndien
-
Chong Kun Dang PharmaceuticalOkändTyp 2 diabetes mellitusKorea, Republiken av
-
PegBio Co., Ltd.AvslutadTyp 2 diabetes mellitusKina
-
Chong Kun Dang PharmaceuticalAvslutadTyp 2 diabetes mellitusKorea, Republiken av
-
Daiichi Sankyo Co., Ltd.AvslutadTyp 2 diabetes mellitusJapan
Kliniska prövningar på Multidisciplinary team care
-
Karolinska University HospitalPhilips Electronics Nederland B.V. acting through Philips CTO organizationAvslutad
-
University of WashingtonPatient-Centered Outcomes Research InstituteAktiv, inte rekryterandePTSD | Fysisk skadaFörenta staterna
-
University Hospital, BordeauxAvslutad
-
Azienda Ospedaliero-Universitaria di ParmaAvslutadBuksmärtor | Andningssvikt | Svaghet | Handikapp | Infektion | MultisjuklighetItalien
-
Ospedale Generale Di Zona Moriggia-PelasciniAvslutadParkinsons sjukdom och Pisa syndromItalien
-
Emory UniversityChildren's Healthcare of AtlantaAvslutadMatnings- och ätstörningar | Undvikande/restriktivt matintagsstörning | MatningsstörningarFörenta staterna
-
The Hospital for Sick ChildrenChild-Bright Network; Ehave; The Governors of the University of AlbertaRekryteringADHD | ASD | CHD - Medfödd hjärtsjukdomKanada
-
The Hospital for Sick ChildrenEhave; Ontario Brain InstituteAvslutadAttention-deficit Hyperactivity DisorderKanada
-
Washington University School of MedicineLogan UniversityAvslutadKronisk smärta | Ryggradens sjukdomFörenta staterna
-
Dana-Farber Cancer InstituteAvslutadBröstcancer | Mag-tarmcancer | Oral cancer riktad terapi | Oral kemoterapiFörenta staterna